Clinicaltrials.gov identifier:
NCT03250078
Prevention
Study Contact Information:
Contact: Tammy Lo, APRN by phone: 203-855-3551 or by email
Contact: Pramila Krumholtz, RN by phone: 203-739-7997 by email
Principal Investigator: Richard Frank, MD
A Pancreatic Cancer Screening Study for High Risk Individuals
About the Study
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with a strong family history of pancreatic cancer, or people with an and at least one first- or second-degree relative with pancreatic cancer. This includes people with (a mutation in , , , , or ) or an inherited mutation in , , CDKN2A, or .
Magnetic Resonance Imaging () will be used to screen for early pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
What the Study Entails
- Participants will undergo a five-minute psychological survey and donation of a blood sample every 6 months for 3 years.
- will be performed annually for 3 years (4 in total). Cost of will be covered by the study.
- Any abnormalities on the will be reviewed by a multi-disciplinary tumor board and discussed with the study participant.
Study Site
Norwalk, CT
Western Connecticut Health Network
Contact: Tammy Lo, APRN by phone: 203-855-3551 or by email
Contact: Pramila Krumholtz, RN by phone: 203-739-7997 by email
Men and women 50-80 years of age can participate if:
- They have a strong family history of pancreatic cancer and
- at least two first-degree relatives with pancreatic cancer
- at least three first-, second-, or third-degree relatives with pancreatic cancer with at least one pancreatic cancer in a first degree relative
- They have (a mutation in , , , , or ) or an inherited mutation in , , CDKN2A, or and have at least one first- or second-degree relative with pancreatic cancer.
People are excluded if they:
- Have a prior history of pancreatic cancer or have cancer
- Have a cancer that required post-treatment chemotherapy within the past 5 years
- Received chemotherapy within the past 6 months
- Have hereditary pancreatitis
- Are known to have a severe reaction to a gadolinium contrast or an exam